Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart

Nature Communications

Volumn 4, Issue , 2013, Pages

  Hoshino, Atsushi ^a   Mita, Yuichiro ^a   Okawa, Yoshifumi ^a   Ariyoshi, Makoto ^a   Iwai Kanai, Eri ^a,b   Ueyama, Tomomi ^a   Ikeda, Koji ^a   Ogata, Takehiro ^a   Matoba, Satoaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJI UNIVERSITY OF INTEGRATIVE MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DOXORUBICIN; PARKIN; PROTEIN P53;

CARDIOVASCULAR DISEASE; DISEASE PREVALENCE; ENZYME ACTIVITY; INHIBITION; PHENOTYPE; RODENT; SENESCENCE;

ARTICLE; CORONARY FLOW RESERVE; HEART FAILURE; HEART MITOCHONDRION; IN VITRO STUDY; IN VIVO STUDY; MITOPHAGY; PHENOTYPE; PREVALENCE; PROTEIN BINDING; PROTEIN TRANSPORT; QUALITY CONTROL; SENESCENCE;

EID: 84882425828     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3308     Document Type: Article

References (54)

1. Mann, D. L. &Bristow, M. R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849 (2005).
2. Rosca, M. G., Tandler, B. &Hoppel, C. L. Mitochondria in cardiac hypertrophy and heart failure. J. Mol. Cell Cardiol. 55, 31-41 (2012).
3. Neubauer, S. The failing heart-an engine out of fuel. N. Engl. J. Med. 356, 1140-1151 (2007).
4. Dai, D. F. et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ. Res. 108, 837-846 (2011).
5. Palaniyandi, S. S., Qi, X., Yogalingam, G., Ferreira, J. C. &Mochly-Rosen, D. Regulation of mitochondrial processes: a target for heart failure. Drug Discov. Today Dis. Mech. 7, e95-e102 (2010).
6. Detmer, S. A. &Chan, D. C. Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 8, 870-879 (2007).
7. Twig, G. et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27, 433-446 (2008).
8. Narendra, D., Tanaka, A., Suen, D. F. &Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803 (2008).
9. Youle, R. J. &Narendra, D. P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9-14 (2011).
10. Okatsu, K. et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat. Commun 3, 1016 (2012).
11. Geisler, S. et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119-131 (2010).
12. Tanaka, A. et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J. Cell Biol. 191, 1367-1380 (2010).
13. Dutta, D., Calvani, R., Bernabei, R., Leeuwenburgh, C. &Marzetti, E. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ. Res. 110, 1125-1138 (2012).
14. Kirkwood, T. B. Understanding the odd science of aging. Cell 120, 437-447 (2005).
15. Finkel, T. Radical medicine: treating ageing to cure disease. Nat. Rev. Mol. Cell Biol. 6, 971-976 (2005).
16. Schriner, S. E. et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308, 1909-1911 (2005).
17. Trifunovic, A. et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429, 417-423 (2004).
18. Vermulst, M. et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat. Genet. 40, 392-394 (2008).
19. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
20. Maejima, Y., Adachi, S., Ito, H., Hirao, K. &Isobe, M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7, 125-136 (2008).
21. Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumour cells by chemotherapeutic drugs. Oncogene 18, 4808-4818 (1999).
22. Spallarossa, P. et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am. J. Physiol. Heart. Circ. Physiol. 297, H2169-H2181 (2009).
23. Campisi, J. &d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729-740 (2007).
24. Nakagawa, T., Lomb, D. J., Haigis, M. C. &Guarente, L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137, 560-570 (2009).
25. Hristova, V. A., Beasley, S. A., Rylett, R. J. &Shaw, G. S. Identification of a novel Zn2-binding domain in the autosomal recessive juvenile Parkinsonrelated E3 ligase parkin. J. Biol. Chem. 284, 14978-14986 (2009).
26. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006).
27. Rodriguez-Navarro, J. A. et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J. Neurochem. 103, 98-114 (2007).
28. Marin-Garcia, J., Akhmedov, A. T. &Moe, G. W. Mitochondria in heart failure: the emerging role of mitochondrial dynamics. Heart Fail Rev. 18, 439-459 (2013).
29. Rambold, A. S. &Lippincott-Schwartz, J. Mechanisms of mitochondria and autophagy crosstalk. Cell Cycle 10, 4032-4038 (2011).
30. Billia, F. et al. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc. Natl Acad. Sci. USA 108, 9572-9577 (2011).
31. Chan, D. C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125, 1241-1252 (2006).
32. Vousden, K. H. &Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283 (2007).
33. Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15, 1082-1087 (2009).
34. Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011).
35. Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014 (2004).
36. Tasdemir, E. et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10, 676-687 (2008).
37. Moll, U. M., Wolff, S., Speidel, D. &Deppert, W. Transcription- independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17, 631-636 (2005).
38. Park, J. Y. et al. p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. Circ. Res. 105, 705-712, 711 p following 712 (2009).
39. Bourdon, A. et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 39, 776-780 (2007).
40. Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11, 1306-1313 (2005).
41. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
42. Huang, C. et al. Preconditioning involves selective mitophagy mediated by Parkin and p62/SQSTM1. PLoS One 6, e20975 (2011).
43. Matsuda, N. et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189, 211-221 (2010).
44. Um, J. W. et al. Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 281, 3595-3603 (2006).
45. Um, J. W. &Chung, K. C. Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 84, 1543-1554 (2006).
46. Kalia, S. K. et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 44, 931-945 (2004).
47. Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl Acad. Sci. USA 108, 16259-16264 (2011).
48. da Costa, C. A. et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat. Cell Biol. 11, 1370-1375 (2009).
49. Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702 (2011).
50. Goldberg, M. S. et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635 (2003).
51. Gulick, J., Subramaniam, A., Neumann, J. &Robbins, J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J. Biol. Chem. 266, 9180-9185 (1991).
52. Claycomb, W. C. et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl Acad. Sci. USA 95, 2979-2984 (1998).
53. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998).
54. Talos, F., Petrenko, O., Mena, P. &Moll, U. M. Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res. 65, 9971-9981 (2005).